Related Experiment Video
Updated: Apr 19, 2026

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
Published on: October 7, 2017
Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability
Elizabeth C Finger1, Julia MacKinley2, Mervin Blair2
1From the Departments of Clinical Neurological Sciences (E.C.F., J.M., M.B., S.J., S.P., A.K.), Medicine (M.B., J.W.), Psychiatry (D.G.V.M.), and Anatomy and Cell Biology (D.G.V.M.), and Graduate Program in Neuroscience (L.D.O.), Schulich School of Medicine and Dentistry, Western University, London, Ontario; Tanz Centre for Research in Neurodegenerative Disease (M.C.T.), University of Toronto, Canada; Freie Universität Berlin (I.D.), Cluster of Excellence Languages of Emotion, Berlin, Germany; and Department of Neurology (K.R., A.B.), University of California San Francisco School of Medicine. Elizabeth.Finger@lhsc.on.ca.
Objective:
To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD).
Methods:
We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia (clinicaltrials.gov registration number NCT01386333). Primary outcome measures were safety and tolerability at each dose. Secondary measures explored efficacy across the combined oxytocin vs placebo groups and examined potential dose-related effects.
Results:
All 3 doses of intranasal oxytocin were safe and well tolerated.
Conclusions:
A multicenter trial is warranted to determine the therapeutic efficacy of long-term intranasal oxytocin for behavioral symptoms in FTD.
Classification Of Evidence:
This study provides Class I evidence that for patients with FTD, intranasal oxytocin is not significantly associated with adverse events or significant changes in the overall neuropsychiatric inventory.
More Related Videos
08:53Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
06:22A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
Published on: September 3, 2021
Related Concept Videos
Drug Dosing: Geriatric Patients
Bioavailability Study Design: Single Versus Multiple Dose Studies
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Dosage Regimens: Designs and Approaches